Britain’s GW Pharmaceuticals has announced that their cannabinoid inhaler may be available by prescription in the UK by 2003, for treatment of multiple sclerosis. “The performance of GW’s medicine has exceeded our own expectations,” founder Geoffrey Guy told the media. “Subject to regulatory approval, we are now on track to deliver our first prescription medicine to the UK market next year.”
Other european nations are also moving forward with implementing medical cannabis. Germany’s Federal Health Ministry has requested that their Federal Association of Pharmacists develop a standardized formulation for producing cannabis extract, so that pharmacists can prepare and provide the medicine.
Meanwhile, Holland’s federal Office of Medicinal Cannabis is preparing a system whereby marijuana produced by licensed growers would be made available in Dutch pharmacies.